Rabies vaccine
Highest phase reached
Phase 3
Drug type
Vaccine component
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Vaccine component
- Drug name
- Rabies vaccine
- rabies vaccine
- Rabies vaccine
- Rabies Vaccine
- Rabies Vaccine (Imovax)
- Rabies vaccine (RabAvert)
- Rabies Vaccine (RabAvert)
- rabies vaccine adsorbed
- Rabies vaccine adsorbed
- rabies vaccines
- Rabies vaccines
- ChEMBL ID
- CHEMBL2107909
- First in class
- No
- Orphan designation
- No
- Condition
- Infections
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000544
- Subject identifier
- D007239
- Condition
- HIV Infections
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000764
- Subject identifier
- D015658
- Condition
- Malaria
- Highest recorded phase
- 3
- Condition identifier
- EFO:0001068
- Subject identifier
- D008288
- Condition
- Malaria, Falciparum
- Highest recorded phase
- 2
- Condition identifier
- EFO:0007444
- Subject identifier
- D016778
- Condition
- Rhabdoviridae Infections
- Highest recorded phase
- 3
- Condition identifier
- EFO:0007469
- Subject identifier
- D018353
- Condition identifier
- EFO_0000544
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000764
- Highest recorded phase
- 2
- Condition identifier
- EFO_0001068
- Highest recorded phase
- 3
- Condition identifier
- EFO_0007444
- Highest recorded phase
- 2
- Condition identifier
- EFO_0007469
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0024618
- Highest recorded phase
- 4
- Event
- immune thrombocytopenic purpura
- Reports
- 9
- Reporting signal score
- 52.1875
- Event
- laryngeal oedema
- Reports
- 3
- Reporting signal score
- 12.5133
- Event
- urticaria
- Reports
- 5
- Reporting signal score
- 9.10519
- NCT00031070
- NCT00308061
- NCT00380393
- NCT00703066
- NCT00866619
- NCT01148459
- NCT01635647
- NCT01658696
- NCT01666925
- NCT03276962
- NCT00317473
- NCT00349713
- NCT00358332
- NCT00460525
- NCT03435874
- NCT03896724
- NCT04661579
- NCT05135273
- NCT05776017
- NCT05790889
- NCT00703521
- NCT00948272
- NCT01228383
- NCT01339312
- NCT01388985
And 16 more, listed on the interactive page.
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (102)
- A Bridging Study of the SYN023 on Healthy Adult Subjects
- A Clinical Trial of Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried in a Population Aged 10 to 60 Years
- A Clinical Trial of Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried in a Population Aged 10-60 Years
- A Comparison of the Safety, PD and PK of a Single Dose of SYN023 Administered With Licensed Rabies Vaccines
- A Phase 1/2b Study of an Investigational Malaria Vaccination Strategy in 5-17 Month Old Infants and Children in Burkina Faso
- A Phase 3 Clinical Trial to Evaluate Long-term Immunogenicity and Boostability of Purified Chick-Embryo Cell Rabies Vaccine in Adults Following Primary Series of Pre/Exposure Prophylaxis.
- A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults
- A Phase Ib/II Study of the Safety and Immunogenicity of the Candidate Rabies Vaccine ChAdOx2 RabG
- A Phase II Trial of a Recombinant Human Anti-Rabies Virus Monoclonal Antibody
- A Phase III Clinical Study to Evaluate SYN023's Efficacy and Safety
- A Safety Study of IMOVAX Polio Vaccine in Selected Cities in China
- A Study of RBI-4000 in Healthy Participants
- A Study of the Safety of IMOVAX Polio™ in China
- A Study to Assess the Safety, Reactogenicity and Immune Response of CureVac's Candidate Rabies mRNA Vaccine in Healthy Adults
- A Study to Evaluate a PIKA Rabies Vaccine（Vero Cell）for Human Use,Freeze-dried
- A Study to Evaluate the One Year Long-term Persistence of Immune Responses Following Two Different Rabies Vaccine Post-exposure Regimens in Chinese Children
- A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Experimental Rabies Vaccine in Healthy Adults
- A Study to Test Experimental Blood Stage Malaria Vaccine in Burkina Faso.
- A Trial of a Peptide-based Group A Streptococcal (GAS) Vaccine Candidate in Healthy Individuals.
- Antibody Production in Immune Disorders
In development for (4)
- HIV infectious disease Phase 2
- Malaria Phase 3
- Plasmodium falciparum malaria Phase 2
- Rhabdoviridae infectious disease Phase 3